Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394493 | 0.87 | ATM (0.56) | CTSLCTSBCTSSCTSKATM | |
| SCHEMBL2228854 | 0.87 | ATM (0.56) | CTSLCTSBCTSSCTSKATM | |
| SCHEMBL4394496 | 0.87 | ATM (0.56) | CTSLCTSBCTSSCTSKATM | |
| SCHEMBL20827892 | 0.87 | CTSK (0.66) | CTSLCTSBCTSSCTSK | |
| SCHEMBL8972419 | 0.87 | CTSK (0.66) | CTSLCTSBCTSSCTSK | |
| SCHEMBL6476159 | 0.85 | CTSK (0.54) | CTSLCTSBCTSSCTSKATM | |
| SCHEMBL16313895 | 0.84 | CTSL (0.51) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL5275932 | 0.83 | CTSK (0.59) | CTSLCTSBCTSSCTSKATM | |
| SCHEMBL5275940 | 0.83 | CTSK (0.59) | CTSLCTSBCTSSCTSKATM | |
| SCHEMBL14648625 | 0.83 | CTSL (0.63) | CTSLCTSBCTSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780039-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2015-10-29 | — | — | US | disclosed |
| US-9138486-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-0621270-B1 | Piperazine derivatives as collagenase inhibitors | SANKYO CO (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-6008228-A | COMPRISING A MIXTURE OF CARRIER MONOGLYCERIDES OF MEDIUM CHAIN-FATTY ACIDS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| EP-0831826-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5643908-A | ANGIOGENESIS INHIBITOR, ANTITUMOR | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0621270-A1 | COLLAGENASE INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1994-10-26 | — | — | EP | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| EP-0386611-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | CTSL 320/4885CTSB 505/4885CTSS 1389/4885 |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | CTSL 320/4885CTSB 505/4885CTSS 1389/4885 |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | CTSL 320/4885CTSB 505/4885CTSS 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.